(RVPH ) – FDA Gives Green Signal To Reviva Pharma’s Late-Stage Schizophrenia Trial

The FDA has notified Reviva Pharmaceuticals Holdings Inc (NASDAQ: RVPH) that it may proceed with Phase 3 trial of its lead candidate, brilaroxazine, a serotonin and dopamine receptor modulator for schizophrenia.

  • The FDA has also signed off an additional Phase 3 trial focused on the long-term safety of brilaroxazine in patients with schizophrenia. 
  • Related: Reviva Pharma Stock Trading Higher On Detailed Positive Schizophrenia Study Results.
  • Both Phase 3 trials will be initiated simultaneously by the end of January 2022.
  • Price Action: RVPH shares are up 16.2% at $3.45 during the premarket session on the last check Monday.

Source link

Leave a Reply

Next Post

The Keys to Podcasting Success in 2022 – Smart Passive Income

Tue Jan 11 , 2022
In this post, I’ll share some of the key trends in podcasting right now, and highlight some ideas for growing your podcast in 2022 and beyond. And join us live on YouTube tomorrow, Tuesday January 11 for OPEN Podcast #1, to learn the strategies for creating powerful podcast content! Table […]